Nucynta 2018 U.S. PROMOTIONAL AUDIT REPORT

Nucynta 2018 U.S. PROMOTIONAL AUDIT REPORT

  • July 2019 •
  • 26 pages •
  • Report ID: 5210512 •
  • Format: PDF
The 5 Key Questions Addressed by this Report:
• How many physicians were reached by Nucynta through reportable promotional activity in 2018 and how does this compare to its peer set in the Neuropathic Pain and Pain – Opioids markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Collegium’s depth of coverage vary within key specialties (e.g., Anesthesiology, Physical Medicine and Rehabilitation, Pain Medicine, Family Medicine, and Internal Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Nucynta throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Nucynta in 2018?

Data Sources and Methodology:
• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
• Over 2,800 paid interactions across 1,900 physicians made on behalf of Nucynta were carefully examined to support our analysis. In addition, interaction data from 13 peer products (e.g. Arymo ER, Belbuca, Embeda, Hysingla ER, Levorphanol, Lyrica, Morphabond ER, Oxaydo, OxyContin, Subsys, Xtampza ER, Zohydro ER, and ZTLido ) was leveraged to provide benchmarking and market insights.